News
Recent health news includes a promising AstraZeneca pill for breast cancer treatment, Pfizer and Arvinas' experimental drug ...
Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...
HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S ...
To sustain momentum, Hims recently announced a deal with Novo Nordisk A/S (NYSE: NVO) to distribute branded Wegovy at ...
Hims asked expert barbers for their takes on the best haircuts for a receding hairline—styles that are flattering, easy to ...
Hims & Hers Health Inc. is cutting more than 4% of its workforce as it pivots away from selling cheap copycat versions of ...
2d
Zacks Investment Research on MSNHims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...
In the wake of sweeping cuts at the FDA’s Office of Prescription Drug Promotion (OPDP), Sen. | In the wake of sweeping cuts ...
The health AI "super app" wants to add more nutrition data to its platform with this buy, its second acquisition of the yar.
HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results